Home Prescription Drugs Tags

View the Latest: Prescription Drugs

Filter

List Grid

471 - 480 of 795 Results

  • Displaced by Hurricane Katrina: Issues and Options for Medicare Beneficiaries

    Issue Brief

    An estimated 200,000 Medicare beneficiaries were displaced by Hurricane Katrina. Medicare played a key role in meeting the health care needs of the elderly and disabled beneficiaries who were displaced by the hurricane. Many of these beneficiaries face new challenges as a direct result of the hurricane. This issue brief identifies issues and challenges for individuals on Medicare affected by the hurricane and offers options for addressing these problems during the transition period. This issue…

  • Medicare Prescription Drug Plans In 2010 and Key Changes Over Five Years

    Issue Brief

    This brief summarizes key findings from the full collection of 2010 Part D Data Spotlights examining key trends in the private stand-alone drug plans available to Medicare beneficiaries. The spotlight is one in a series analyzing key aspects of the Medicare Part D drug plans that will be available to beneficiaries in 2010. The analysis was conducted jointed by Jack Hoadley and Laura Summer of Georgetown University, Elizabeth Hargrave of NORC at the University of Chicago,…

  • Additional Findings from the National Surveys of Doctors and Pharmacists

    Poll Finding

    Two Kaiser Family Foundation national surveys of doctors and pharmacists examine additional findings on their views and experiences on a wide range of health care issues. The topics covered in the surveys include views and experiences with medical errors and quality issues, use of health care information technology, prescription drug advertisements, views on Medicaid provisions, doctors' willingness to see Medicaid and Medicare patients, and physicians' views of conscience-clause provisions. The Kaiser Family Foundation National Survey…

  • How Can Trump Administration Regulations Be Reversed?

    Issue Brief

    With the inauguration of President Biden and Democrats holding a slim majority in Congress, policymakers are likely to consider whether and how to reverse various health policy regulations issued by the Trump Administration.

  • A Status Report on Prescription Drug Policies and Proposals at the Start of the Biden Administration

    Issue Brief

    This brief provides a status update on prescription drug final rules advanced by the Trump Administration in its final months related to Medicare, importation, and 340B pricing for insulin and epinephrine, and an overview of key drug pricing proposals related to Medicare and prescription drug prices generally that were voted on but not enacted in the previous Congress that may return to the forefront of health policy discussions in the coming years.

  • Skepticism Surrounding ADHD Diagnoses and Medication — The Monitor

    Feature

    This volume examines the impact of recent executive actions on federal health communication, along with concerns and stigmas surrounding ADHD diagnoses and treatments, including skepticism about pharmaceutical influence on medication promotion. It also explores distrust in food regulations following the FDA’s ban on Red Dye No. 3.

  • Health Spending Issues to Watch This Year

    Issue Brief

    KFF and the Peterson Center on Healthcare examine market trends contributing to rising health costs and identify several potential federal and state policy issues to watch throughout 2025, including high-cost drugs, federal funding cuts, and workforce shortages.

  • The Effect of Delaying the Selection of Small Molecule Drugs for Medicare Drug Price Negotiation

    Policy Watch

    In a new Trump administration executive order, the Secretary of HHS is directed to work with Congress to implement a change in law to delay negotiation of so-called “small molecule” drugs under the Inflation Reduction Act's Medicare Drug Price Negotiation Program for an additional 4 years. This brief analyzes how many of the drugs previously selected for negotiation would not have been eligible if this policy had been in place at the time.

  • Allowing Medicare to Negotiate Drug Prices Remains Broadly Popular Among Voters, Though Most Are Unaware of the Law and Its Projected Savings

    News Release

    Allowing Medicare to negotiate drug prices on behalf of older Americans remains broadly popular across partisans, though many voters are unaware of the new law and the billions of dollars it is expected to save in 2026, a new KFF Health Tracking Poll finds.A large majority (85%) of voters say they support allowing the federal government to negotiate the price of some prescription drugs for people with Medicare. This includes at least three quarters of…